[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myomauterus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myomauterus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,69,96,122,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633409","reducing-blood-loss-during-myomectomyuterine-artery-ligation-vs-pericervical-tourniquet-100633409",false,"NCT07526311","Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet","Bilateral Uterine Artery Ligation Versus Pericervical Mechanical Tourniquet Application in Reducing Intraoperative Blood Loss During Transabdominal Myomectomy.","* Inclusion Criteria:\n\n  * Female participants aged 25 to 48 years\n  * Body mass index less than 35 kg\u002Fm²\n  * Symptomatic uterine myomas requiring surgical treatment\n  * Intramural myomas classified as FIGO types 3 to 6\n  * Diagnosis confirmed by transvaginal ultrasound and\u002For magnetic resonance imaging\n  * Maximum diameter of the largest myoma 20 cm or less\n  * Scheduled for elective transabdominal myomectomy\n  * Able and willing to provide written informed consent\n* Exclusion Criteria:\n\n  * Submucosal, intracavitary, pedunculated subserosal, cervical, or adnexal myomas\n  * FIGO types 0, 1, 2, 7, or 8 myomas\n  * History of pelvic inflammatory disease or peritonitis\n  * Previous abdominal or pelvic surgery for non-obstetric causes\n  * Previous uterine surgery\n  * Use of hormonal therapy within the previous 3 months\n  * Known bleeding disorder\n  * Use of anticoagulant or antiplatelet therapy\n  * Preoperative hemoglobin less than 10 g\u002FdL\n  * Body mass index 35 kg\u002Fm² or greater\n  * Intraoperative conversion from myomectomy to hysterectomy","FEMALE","25 Years","48 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare two surgical techniques for reducing blood loss during transabdominal myomectomy in women with symptomatic uterine fibroids. The main question it aims to answer is whether bilateral uterine artery ligation reduces intraoperative blood loss more effectively than pericervical mechanical tourniquet application, without increasing operative complications. Researchers will compare bilateral uterine artery ligation with pericervical mechanical tourniquet application during open myomectomy to evaluate blood loss and surgical safety. Participants will undergo elective transabdominal myomectomy and will be randomly assigned to one of the two vascular control techniques before myoma enucleation.",[27,28],"Myoma;Uterus","Blood Loss",[30,31,32,33],"uterine artery ligation","peri cervical mechanical tourniquet","blood loss","myomectomy","RECRUITING","2026-04-10",{"date":37,"type":38},"2026-04-13","ACTUAL",{"date":35,"type":21},{"date":41,"type":21},"2027-04-10",{"name":43,"class":44},"Cairo University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100622995","ergometrine-versus-carbetocin-to-decrease-blood-loss-in-myomectomy-100622995","NCT07390864","Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy","Intramyometrial Ergometrine Injection Versus Intramyometrial Carbetocin Injection to Decrease Blood Loss During and After Abdominal Myomectomy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Female participants aged 25 to 48 years\n* Body mass index (BMI) \\\u003C 35 kg\u002Fm²\n* Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms)\n* Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagnosed by transvaginal ultrasonography or magnetic resonance imaging\n* Maximum diameter of the largest myoma ≤ 20 cm\n* Eligible for and scheduled to undergo abdominal myomectomy\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* FIGO type 0, 1, 2, 7, or 8 myomas (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal)\n* History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection\n* History of prior uterine surgery\n* Use of hormonal treatment within 3 months prior to enrollment\n* Contraindication to methylergometrine or carbetocin, including:\n* Known drug allergy\n* Hypertension\n* Cardiac or pulmonary disease\n* Chronic endocrine or metabolic disease (e.g., diabetes mellitus)\n* Renal or hepatic impairment\n* High risk of bleeding, including:\n* Known bleeding disorders\n* Current use of antiplatelet or anticoagulant therapy\n* Preoperative anemia (hemoglobin \\\u003C 10 g\u002FdL)\n* BMI ≥ 35 kg\u002Fm²\n* Intraoperative conversion from myomectomy to hysterectomy",{"count":20,"type":21},[24],"The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.\n\nThe main questions it aims to answer are:\n\nDoes intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy?\n\nDoes intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy?\n\nIs there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop?\n\nResearchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes.\n\nParticipants will:\n\nUndergo abdominal myomectomy for uterine fibroids\n\nReceive either intramyometrial ergometrine or intramyometrial carbetocin during surgery\n\nBe monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion",[27],[58,59,28,60],"Ergometrine","Carbetocin","Abdominal Myomectomy","2026-02-01",{"date":63,"type":38},"2026-02-05",{"date":65,"type":38},"2026-01-18",{"date":67,"type":21},"2026-08-30",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100614491","incidence-of-intrauterine-adhesions-after-myomectomy-with-intrauterine-anti-adhesion-gel-100614491","NCT07280286","Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel","Incidence of Intrauterine Adhesions Following Myomectomies With the Use of an Intrauterine Anti-adhesion Gel","Inclusion Criteria:\n\n* Age between 18 and 45 years;\n* BMI 18-35;\n* One or more fibroids diagnosed via ultrasound;\n* First myomectomy or uterine surgery;\n* Incomplete reproductive plans and\u002For infertility;\n* Adequate immune, respiratory, liver, cardiac, bone marrow, and kidney function;\n* Compliance and psychological ability to follow study procedures;\n* Acceptance and signing of informed consent.\n\nExclusion Criteria:\n\n* Age under 18 years;\n* Age over 46 years;\n* Pregnancy or breastfeeding;\n* History of intrauterine adhesions;\n* Diagnosis or suspicion of malignant gynecological pathologies and\u002For autoimmune diseases;\n* Completed reproductive plans;\n* Severe respiratory, bone marrow, liver, or kidney dysfunction preventing safe surgical access.","18 Years","45 Years",{"count":79,"type":21},62,[24],"This prospective randomized study aims to evaluate whether the application of an intrauterine anti-adhesion gel reduces the incidence of intrauterine adhesions (IUAs) following robotic-assisted laparoscopic myomectomy. Intrauterine adhesions may develop after endometrial trauma during surgery and can negatively affect menstrual function, fertility, and future pregnancy outcomes. Robotic myomectomy offers a minimally invasive approach, but postoperative adhesion formation remains a concern.\n\nSixty-two women undergoing myomectomy will be randomized to receive either intrauterine anti-adhesion gel (intervention group) or no adhesion-prevention method (control group). Adhesions will be assessed by ultrasound and hysteroscopy during follow-up. Secondary outcomes include reproductive results over a 24-month period, such as implantation rate, clinical pregnancy, miscarriage, live birth, pregnancy complications, and neonatal outcomes.\n\nThe study seeks to determine whether combining a minimally invasive surgical approach with an intrauterine gel provides additional protection against adhesion formation and improves fertility-related outcomes.",[27,83],"Adhesion; Uterus, Internal",[85,33],"intrauterine adhesions","NOT_YET_RECRUITING","2025-12-03",{"date":89,"type":38},"2025-12-12",{"date":91,"type":21},"2025-12-09",{"date":93,"type":21},"2028-11-20",{"name":95,"class":44},"Federico II University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":45},"100583937","prevention-of-hemorhagic-risk-in-upper-myomectomy-by-use-of-misoprostol-100583937","NCT06882824","Prevention of HEMOrhagic Risk in Upper MYOmeCTomy by Use of Misoprostol.","HEMOMYOC","Inclusion Criteria:\n\n* Patient aged 18 to 43\n* Symptomatic myomas (bleeding, pain or infertility)\n* Indication for laparoscopic myomectomy Fibroma ≤ 10cm or number ≤ to 4 fibroids\n* Indication for myomectomy by laparotomy Fibroma \\> 10cm, Number \\> to 4 fibroids\n* OTAU possible intraoperatively (Clip on uterine artery and tourniquet placement)\n* Speak and understand French\n* Affiliated with a social security scheme.\n\nExclusion Criteria:\n\n* History of major uterine surgery or myomectomy (excluding hysteroscopic myomectomy)\n* Allergy to misoprostol and lactose\n* Patients with hypersensitivity to misoprostol and\u002For other prostaglandins or to any of the product's excipients.\n* Patients taking aspirin or anti-coagulants\n* Patients with haemostasis disorders\n* Malnourished patients\n* Patients with hepatic or renal insufficiency\n* Pregnancy, suspected ectopic pregnancy and breast-feeding women.\n* Minors\n* Guardianship, curatorship, deprived of liberty, safeguard of justice","43 Years",{"count":105,"type":21},80,[24],"In France, uterine fibroids or leiomyomas are the most common benign tumour in women of childbearing age.\n\nIn 30% of cases, fibroids are symptomatic (menorrhagia, anaemia, pain), in which case surgical management is indicated. This is known as myomectomy, and can be performed by hysteroscopy, laparoscopy (laparoscopy) or laparotomy, depending on the number, size and position of the fibroids.\n\nIntraoperative bleeding is the main surgical difficulty. For this reason, a number of studies have focused on ways of minimizing the risk of bleeding.\n\nA good surgical indication, prevention of anaemia (iron deficiency) and transient occlusion of the uterine arteries during surgery help to reduce this risk. There are also drugs available to reduce intraoperative bleeding, but few studies have been carried out to assess their real effectiveness. One such product is Misoprostol, commonly used in gynecology. Its muscle-contracting properties suggest that it could have a beneficial effect on bleeding during surgery. What's more, this treatment has been used for many years and is reputed to be very well tolerated. The most frequent side effects are digestive, with a risk of abdominal pain in the form of cramps, nausea or vomiting.\n\nThe investigators therefore decided to set up the HEMOMYOC study to demonstrate a significant reduction in bleeding during laparotomy or laparoscopic myomectomy after taking oral misoprostol in combination with transient occlusion of the uterine arteries, compared with placebo. It would seem that the ease of use and good tolerance of misoprostol, in combination with transient occlusion of the uterine arteries, could be of real benefit in preventing intraoperative morbidity in myomectomies, whatever the surgical approach. To date, no studies have been carried out in this area.",[27,109],"Myomectomy; Surgical Blood Loss",[33,111,112],"surgical blood loss","misoprostol","2025-09-19",{"date":115,"type":38},"2025-09-24",{"date":117,"type":38},"2025-03-12",{"date":119,"type":21},"2028-04-17",{"name":121,"class":44},"University Hospital, Clermont-Ferrand",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100438499","ultrasound-evaluation-of-the-myometrium-using-the-musa-terminology-comparison-with-histology-100438499","NCT04990076","Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology","Ultrasound Evaluation of the Myometrium Using the MUSA Terminology, Comparison With Histology.","MUSA1","Inclusion Criteria:\n\nConsecutive patients planned to undergo hysterectomy for myometrial pathology of more then 1cm (e.g. fibroid, focal adenomyosis, uterine sarcoma).\n\nExclusion Criteria:\n\n* Patient's refusal\n* Age \\\u003C 18 years\n* Polymyomatous uterus\n* Myometrial lesion with a diameter less then 10mm\n* Patients currently treated for another cancer\n* Patients with ovarian pathology, endometrial pathology of cervical pathology\n* Power morcellation",{"count":131,"type":21},1500,"OBSERVATIONAL","The main objective is to evaluate the diagnostic accuracy of the MUSA terms and definitions, as defined in the paper by Van den Bosch T, Dueholm M, ea. in 2015, to differentiate between different types of myometrial lesions of more than 1 cm. The primary aim is the diagnostic accuracy of the MUSA terms and definitions and the secondary aim the development of a prediction model.",[27,135],"Sarcoma Uterus","2024-07-01",{"date":138,"type":38},"2024-07-03",{"date":140,"type":38},"2020-03-11",{"date":142,"type":21},"2026-03-30",{"name":144,"class":44},"Universitaire Ziekenhuizen KU Leuven",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100510872","the-impact-of-myomectomy-on-ivf-outcomes-100510872","NCT05932082","The Impact of Myomectomy on IVF Outcomes","The Impact of Myomectomy on IVF Outcomes: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female aged between 20-40 years old.\n2. Primary or secondary infertility consisting of following factors rather than uterine factors: male factors, ovulation disorders, fallopian tube factors, endometriosis, other non-uterine factors including infertility with unexplained reason.\n3. Myoma: FIGO type 4-6 discovered by MRI with the maximum diameter surgically targeted between 4-6cm; Single myoma, or multiple myomas with non-surgically targeted intramural or subserous myoma(s) \\\u003C 2cm in maximum diameter.\n4. Justifying the IVF criteria and willing to undergo IVF.\n\nExclusion Criteria:\n\n1. Not meeting all the inclusion criteria.\n2. Complicated with infertility factors of uterine factors or diseases, including adenomyosis, endometrial adhesion, endometritis, submucous myoma. However, resectable endometrial polyps need not be excluded.\n3. Complicated with malignancies or borderline tumors of the reproductive tract\n4. Complicated with other malignancies not been treated or still being treated.\n5. Complicated with active pelvic inflammatory disease.\n6. Previously receiving cytotoxic therapy or abdominal-abdominal chemoradiotherapy.\n7. Previous uterine body surgery, including but not limited to: myomectomy, resection for adenomyosis lesions, uterine artery embolization, uterine tumor coagulation (high energy focused ultrasound or electrocoagulation, hysteroscopically myomectomy. However, diagnostic hysteroscopy, diagnostic curettage and polypectomy need not be excluded.\n8. No willing to undergo IVF.\n9. Unable to be followed-up.","20 Years","40 Years",{"count":155,"type":21},792,[24],"In 2% to 3% infertility women, myoma is the only factor relevant to their infertility. However, the effects of intramural myoma on fertility are controversial. For infertile women with intramural myoma (types IV, V, VI of FIGO system) of 4 to 6 cm diameter, it is not clear whether myomectomy could improve pregnancy outcomes, especially in women undergoing ART. Besides, rigorous clinical research is needed to explore the changes and relevant biomarkers of endometrial receptivity through multi-omics study in patients undergoing myomectomy and ART treatment.\n\nMethod Intervention and follow-up: (1) For the control group, evaluation protocols such as salpingography and\u002For laparoscopic tubal fluxation should be implemented to identify disorders such as hydrosalpinx. (2) Imaging evaluation: all pelvic MRI were performed. Other options such as transvaginal ultrasound are not excluded, but won't replace MRI. Enhanced MRI or DWI may be considered, but are not always required. (3) Surgical intervention: laparoscopic myomectomy is preferred, and abdominal myomectomy is also acceptable. (4) IVF treatment: the IVF regimen should include detailed records of the downregulation plan, number of cycles, frozen or fresh blastocysts.\n\nStudy endpoints\n\n(1) Primary study endpoint: Live birth rate after IVF. (2) Secondary study endpoints: Clinical pregnancy rate after IVF; Cumulative pregnancy rate after IVF; Biochemical pregnancy rate after IVF; Sustained pregnancy rate after IVF (≥20 weeks); Miscarriage rate after IVF; Cycles of IVF; Pregnancy-related complications; Perinatal maternal and neonatal complications. (3) Exploratory endpoints: The correlation between imaging index and assisted reproductive outcomes, including endometrial thickness, uterine volume, type of endometrial echo, uterine contraction; endometrial vascular index (VI), flow index (FI), tubular flow index (VFI); uterine artery pulsation index (PI), uterine artery resistance index (RI), systolic\u002Fdiastolic blood pressure of uterine artery (S\u002FD).\n\nThe correlation between endometrial receptivity and assisted reproductive outcomes is analyzed based on transcriptomics, metabolomics, methylation and proteomics in samples from peripheral blood, endometrial biopsy, endometrial exfoliated cells, cervical exfoliated cells and myoma.",[27,159,160],"IVF","Surgery","2023-08-02",{"date":163,"type":38},"2023-08-04",{"date":165,"type":21},"2023-09-01",{"date":167,"type":21},"2026-09-01",{"name":169,"class":44},"Peking Union Medical College Hospital"]